Technical Analysis for ADPT - Adaptive Biotechnologies Corporation
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 4.42 | -1.34% | -0.06 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | -1.34% | |
| Wide Bands | Range Expansion | -1.34% |
| Alert | Time |
|---|---|
| Possible NR7 | about 17 hours ago |
| Up 1% | about 18 hours ago |
| 60 Minute Opening Range Breakout | about 20 hours ago |
| 2x Volume Pace | about 21 hours ago |
| 1.5x Volume Pace | about 21 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/07/2024
Adaptive Biotechnologies Corporation Description
Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Disease Infectious Diseases Drug Discovery Leukemia Blood Test Diagnostic Tests Blood Cancers Treatment Of A Range Of Cancer Residual Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.7 |
| 52 Week Low | 2.28 |
| Average Volume | 1,120,697 |
| 200-Day Moving Average | 3.99 |
| 50-Day Moving Average | 4.96 |
| 20-Day Moving Average | 5.21 |
| 10-Day Moving Average | 5.40 |
| Average True Range | 0.41 |
| RSI (14) | 38.65 |
| ADX | 28.89 |
| +DI | 20.55 |
| -DI | 28.37 |
| Chandelier Exit (Long, 3 ATRs) | 5.48 |
| Chandelier Exit (Short, 3 ATRs) | 5.55 |
| Upper Bollinger Bands | 6.38 |
| Lower Bollinger Band | 4.03 |
| Percent B (%b) | 0.17 |
| BandWidth | 45.14 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.15 |
| MACD Histogram | -0.1532 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.77 | ||||
| Resistance 3 (R3) | 4.78 | 4.67 | 4.71 | ||
| Resistance 2 (R2) | 4.67 | 4.58 | 4.67 | 4.69 | |
| Resistance 1 (R1) | 4.55 | 4.53 | 4.54 | 4.54 | 4.67 |
| Pivot Point | 4.44 | 4.44 | 4.43 | 4.43 | 4.44 |
| Support 1 (S1) | 4.31 | 4.35 | 4.30 | 4.30 | 4.17 |
| Support 2 (S2) | 4.20 | 4.29 | 4.20 | 4.15 | |
| Support 3 (S3) | 4.08 | 4.20 | 4.13 | ||
| Support 4 (S4) | 4.07 |
